Implementing SMAD6 onto an existing PAH gene panel provides a feasible approach to routinely and cost-effectively screen for pathogenic SMAD6 variants in patients with (CHD-A)PAH. The gene discussed is SMAD6; the disease is pulmonary arterial hypertension.